Last 12 months
Inside the activity.
0 purchase rows · 13 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 4 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 21, 2020 Filed Apr 23, 2020 21:29 UTC |
GOULD PAUL ADirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 9,985 | Not disclosed Strike: $26.77 | Not disclosed |
DisclosureSEC source: 0001570585-20-000127 · wf-form4_158767735236095.xml · derivative · entry 3 GOULD PAUL A · CIK 0001018211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 9,985 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:29 UTC |
GOULD PAUL ADirector
|
GrantShare Option A (right to buy) · Derivative | 4,634 | Not disclosed Strike: $29.22 | Not disclosed |
DisclosureSEC source: 0001570585-20-000127 · wf-form4_158767735236095.xml · derivative · entry 2 GOULD PAUL A · CIK 0001018211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,634 Underlying: Class A Ordinary Shares · 4,634 shares Expires 2023-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:29 UTC |
GOULD PAUL ADirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 4,634 | Not disclosed Strike: $29.22 | Not disclosed |
DisclosureSEC source: 0001570585-20-000127 · wf-form4_158767735236095.xml · derivative · entry 1 GOULD PAUL A · CIK 0001018211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 4,634 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:27 UTC |
BRACKEN CHARLES H REVP & CFO
|
GrantShare Appreciation Rights C · Derivative | 169,960 | Not disclosed Strike: $27.34 | Not disclosed |
DisclosureSEC source: 0001570585-20-000122 · wf-form4_158767723236526.xml · derivative · entry 12 BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,960 Underlying: Class C Ordinary Shares · 169,960 shares Expires 2023-06-24 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:27 UTC |
BRACKEN CHARLES H REVP & CFO
|
Disposition to issuerShare Appreciation Rights C · Derivative | 169,960 | Not disclosed Strike: $27.34 | Not disclosed |
DisclosureSEC source: 0001570585-20-000122 · wf-form4_158767723236526.xml · derivative · entry 11 BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 169,960 shares Expires 2020-06-24 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:27 UTC |
BRACKEN CHARLES H REVP & CFO
|
GrantShare Appreciation Rights C · Derivative | 339,754 | Not disclosed Strike: $25.84 | Not disclosed |
DisclosureSEC source: 0001570585-20-000122 · wf-form4_158767723236526.xml · derivative · entry 10 BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,754 Underlying: Class C Ordinary Shares · 339,754 shares Expires 2023-06-24 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:27 UTC |
BRACKEN CHARLES H REVP & CFO
|
Disposition to issuerShare Appreciation Rights C · Derivative | 339,754 | Not disclosed Strike: $25.84 | Not disclosed |
DisclosureSEC source: 0001570585-20-000122 · wf-form4_158767723236526.xml · derivative · entry 9 BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 339,754 shares Expires 2020-06-24 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:27 UTC |
BRACKEN CHARLES H REVP & CFO
|
GrantShare Appreciation Rights C · Derivative | 37,435 | Not disclosed Strike: $29.05 | Not disclosed |
DisclosureSEC source: 0001570585-20-000122 · wf-form4_158767723236526.xml · derivative · entry 8 BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,435 Underlying: Class C Ordinary Shares · 37,435 shares Expires 2023-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:27 UTC |
BRACKEN CHARLES H REVP & CFO
|
Disposition to issuerShare Appreciation Rights C · Derivative | 37,435 | Not disclosed Strike: $29.05 | Not disclosed |
DisclosureSEC source: 0001570585-20-000122 · wf-form4_158767723236526.xml · derivative · entry 7 BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 37,435 shares Expires 2020-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:27 UTC |
BRACKEN CHARLES H REVP & CFO
|
GrantShare Appreciation Rights C · Derivative | 74,888 | Not disclosed Strike: $27.13 | Not disclosed |
DisclosureSEC source: 0001570585-20-000122 · wf-form4_158767723236526.xml · derivative · entry 6 BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,888 Underlying: Class C Ordinary Shares · 74,888 shares Expires 2023-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:27 UTC |
BRACKEN CHARLES H REVP & CFO
|
Disposition to issuerShare Appreciation Rights C · Derivative | 74,888 | Not disclosed Strike: $27.13 | Not disclosed |
DisclosureSEC source: 0001570585-20-000122 · wf-form4_158767723236526.xml · derivative · entry 5 BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 74,888 shares Expires 2020-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:27 UTC |
BRACKEN CHARLES H REVP & CFO
|
GrantShare Appreciation Rights A · Derivative | 170,684 | Not disclosed Strike: $27.71 | Not disclosed |
DisclosureSEC source: 0001570585-20-000122 · wf-form4_158767723236526.xml · derivative · entry 4 BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,684 Underlying: Class A Ordinary Shares · 170,684 shares Expires 2023-06-24 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:27 UTC |
BRACKEN CHARLES H REVP & CFO
|
Disposition to issuerShare Appreciation Rights A · Derivative | 170,684 | Not disclosed Strike: $27.71 | Not disclosed |
DisclosureSEC source: 0001570585-20-000122 · wf-form4_158767723236526.xml · derivative · entry 3 BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 170,684 shares Expires 2020-06-24 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:27 UTC |
BRACKEN CHARLES H REVP & CFO
|
GrantShare Appreciation Rights A · Derivative | 37,610 | Not disclosed Strike: $29.45 | Not disclosed |
DisclosureSEC source: 0001570585-20-000122 · wf-form4_158767723236526.xml · derivative · entry 2 BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,610 Underlying: Class A Ordinary Shares · 37,610 shares Expires 2023-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:27 UTC |
BRACKEN CHARLES H REVP & CFO
|
Disposition to issuerShare Appreciation Rights A · Derivative | 37,610 | Not disclosed Strike: $29.45 | Not disclosed |
DisclosureSEC source: 0001570585-20-000122 · wf-form4_158767723236526.xml · derivative · entry 1 BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 37,610 shares Expires 2020-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:32 UTC |
WARGO J DAVIDDirector
|
GrantShare Option C (right to buy) · Derivative | 4,614 | Not disclosed Strike: $28.82 | Not disclosed |
DisclosureSEC source: 0001570585-20-000134 · wf-form4_158767752830026.xml · derivative · entry 6 WARGO J DAVID · CIK 0001082013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,614 Underlying: Class C Ordinary Shares · 4,614 shares Expires 2023-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:32 UTC |
WARGO J DAVIDDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 4,614 | Not disclosed Strike: $28.82 | Not disclosed |
DisclosureSEC source: 0001570585-20-000134 · wf-form4_158767752830026.xml · derivative · entry 5 WARGO J DAVID · CIK 0001082013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 4,614 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:32 UTC |
WARGO J DAVIDDirector
|
GrantShare Option C (right to buy) · Derivative | 9,985 | Not disclosed Strike: $26.77 | Not disclosed |
DisclosureSEC source: 0001570585-20-000134 · wf-form4_158767752830026.xml · derivative · entry 4 WARGO J DAVID · CIK 0001082013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,985 Underlying: Class C Ordinary Shares · 9,985 shares Expires 2023-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:32 UTC |
WARGO J DAVIDDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 9,985 | Not disclosed Strike: $26.77 | Not disclosed |
DisclosureSEC source: 0001570585-20-000134 · wf-form4_158767752830026.xml · derivative · entry 3 WARGO J DAVID · CIK 0001082013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 9,985 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:32 UTC |
WARGO J DAVIDDirector
|
GrantShare Option A (right to buy) · Derivative | 4,634 | Not disclosed Strike: $29.22 | Not disclosed |
DisclosureSEC source: 0001570585-20-000134 · wf-form4_158767752830026.xml · derivative · entry 2 WARGO J DAVID · CIK 0001082013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,634 Underlying: Class A Ordinary Shares · 4,634 shares Expires 2023-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:32 UTC |
WARGO J DAVIDDirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 4,634 | Not disclosed Strike: $29.22 | Not disclosed |
DisclosureSEC source: 0001570585-20-000134 · wf-form4_158767752830026.xml · derivative · entry 1 WARGO J DAVID · CIK 0001082013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 4,634 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:29 UTC |
FRIES MICHAEL TDirector · President & CEO
|
GrantShare Appreciation Rights C · Derivative | 967,468 | Not disclosed Strike: $27.34 | Not disclosed |
DisclosureSEC source: 0001570585-20-000126 · wf-form4_158767733001345.xml · derivative · entry 12 FRIES MICHAEL T · CIK 0001058725 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 967,468 Underlying: Class C Ordinary Shares · 967,468 shares Expires 2023-06-24 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:29 UTC |
FRIES MICHAEL TDirector · President & CEO
|
Disposition to issuerShare Appreciation Rights C · Derivative | 967,468 | Not disclosed Strike: $27.34 | Not disclosed |
DisclosureSEC source: 0001570585-20-000126 · wf-form4_158767733001345.xml · derivative · entry 11 FRIES MICHAEL T · CIK 0001058725 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 967,468 shares Expires 2020-06-24 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:29 UTC |
FRIES MICHAEL TDirector · President & CEO
|
GrantShare Appreciation Rights C · Derivative | 1,933,985 | Not disclosed Strike: $25.84 | Not disclosed |
DisclosureSEC source: 0001570585-20-000126 · wf-form4_158767733001345.xml · derivative · entry 10 FRIES MICHAEL T · CIK 0001058725 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,933,985 Underlying: Class C Ordinary Shares · 1,933,985 shares Expires 2023-06-24 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:29 UTC |
FRIES MICHAEL TDirector · President & CEO
|
Disposition to issuerShare Appreciation Rights C · Derivative | 1,933,985 | Not disclosed Strike: $25.84 | Not disclosed |
DisclosureSEC source: 0001570585-20-000126 · wf-form4_158767733001345.xml · derivative · entry 9 FRIES MICHAEL T · CIK 0001058725 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 1,933,985 shares Expires 2020-06-24 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:29 UTC |
FRIES MICHAEL TDirector · President & CEO
|
GrantShare Appreciation Rights C · Derivative | 42,788 | Not disclosed Strike: $29.05 | Not disclosed |
DisclosureSEC source: 0001570585-20-000126 · wf-form4_158767733001345.xml · derivative · entry 8 FRIES MICHAEL T · CIK 0001058725 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,788 Underlying: Class C Ordinary Shares · 42,788 shares Expires 2023-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:29 UTC |
FRIES MICHAEL TDirector · President & CEO
|
Disposition to issuerShare Appreciation Rights C · Derivative | 42,788 | Not disclosed Strike: $29.05 | Not disclosed |
DisclosureSEC source: 0001570585-20-000126 · wf-form4_158767733001345.xml · derivative · entry 7 FRIES MICHAEL T · CIK 0001058725 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 42,788 shares Expires 2020-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:29 UTC |
FRIES MICHAEL TDirector · President & CEO
|
GrantShare Appreciation Rights C · Derivative | 85,596 | Not disclosed Strike: $27.13 | Not disclosed |
DisclosureSEC source: 0001570585-20-000126 · wf-form4_158767733001345.xml · derivative · entry 6 FRIES MICHAEL T · CIK 0001058725 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,596 Underlying: Class C Ordinary Shares · 85,596 shares Expires 2023-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:29 UTC |
FRIES MICHAEL TDirector · President & CEO
|
Disposition to issuerShare Appreciation Rights C · Derivative | 85,596 | Not disclosed Strike: $27.13 | Not disclosed |
DisclosureSEC source: 0001570585-20-000126 · wf-form4_158767733001345.xml · derivative · entry 5 FRIES MICHAEL T · CIK 0001058725 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 85,596 shares Expires 2020-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:29 UTC |
FRIES MICHAEL TDirector · President & CEO
|
GrantShare Appreciation Rights A · Derivative | 971,587 | Not disclosed Strike: $27.71 | Not disclosed |
DisclosureSEC source: 0001570585-20-000126 · wf-form4_158767733001345.xml · derivative · entry 4 FRIES MICHAEL T · CIK 0001058725 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 971,587 Underlying: Class A Ordinary Shares · 971,587 shares Expires 2023-06-24 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:29 UTC |
FRIES MICHAEL TDirector · President & CEO
|
Disposition to issuerShare Appreciation Rights A · Derivative | 971,587 | Not disclosed Strike: $27.71 | Not disclosed |
DisclosureSEC source: 0001570585-20-000126 · wf-form4_158767733001345.xml · derivative · entry 3 FRIES MICHAEL T · CIK 0001058725 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 971,587 shares Expires 2020-06-24 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:29 UTC |
FRIES MICHAEL TDirector · President & CEO
|
GrantShare Appreciation Rights A · Derivative | 42,988 | Not disclosed Strike: $29.45 | Not disclosed |
DisclosureSEC source: 0001570585-20-000126 · wf-form4_158767733001345.xml · derivative · entry 2 FRIES MICHAEL T · CIK 0001058725 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,988 Underlying: Class A Ordinary Shares · 42,988 shares Expires 2023-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:29 UTC |
FRIES MICHAEL TDirector · President & CEO
|
Disposition to issuerShare Appreciation Rights A · Derivative | 42,988 | Not disclosed Strike: $29.45 | Not disclosed |
DisclosureSEC source: 0001570585-20-000126 · wf-form4_158767733001345.xml · derivative · entry 1 FRIES MICHAEL T · CIK 0001058725 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 42,988 shares Expires 2020-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:31 UTC |
ROMRELL LARRY EDirector
|
GrantShare Option C (right to buy) · Derivative | 4,614 | Not disclosed Strike: $28.82 | Not disclosed |
DisclosureSEC source: 0001570585-20-000131 · wf-form4_158767745571321.xml · derivative · entry 6 ROMRELL LARRY E · CIK 0001120556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,614 Underlying: Class C Ordinary Shares · 4,614 shares Expires 2023-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:31 UTC |
ROMRELL LARRY EDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 4,614 | Not disclosed Strike: $28.82 | Not disclosed |
DisclosureSEC source: 0001570585-20-000131 · wf-form4_158767745571321.xml · derivative · entry 5 ROMRELL LARRY E · CIK 0001120556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 4,614 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:31 UTC |
ROMRELL LARRY EDirector
|
GrantShare Option C (right to buy) · Derivative | 9,985 | Not disclosed Strike: $26.77 | Not disclosed |
DisclosureSEC source: 0001570585-20-000131 · wf-form4_158767745571321.xml · derivative · entry 4 ROMRELL LARRY E · CIK 0001120556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,985 Underlying: Class C Ordinary Shares · 9,985 shares Expires 2023-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:31 UTC |
ROMRELL LARRY EDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 9,985 | Not disclosed Strike: $26.77 | Not disclosed |
DisclosureSEC source: 0001570585-20-000131 · wf-form4_158767745571321.xml · derivative · entry 3 ROMRELL LARRY E · CIK 0001120556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 9,985 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:31 UTC |
ROMRELL LARRY EDirector
|
GrantShare Option A (right to buy) · Derivative | 4,634 | Not disclosed Strike: $29.22 | Not disclosed |
DisclosureSEC source: 0001570585-20-000131 · wf-form4_158767745571321.xml · derivative · entry 2 ROMRELL LARRY E · CIK 0001120556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,634 Underlying: Class A Ordinary Shares · 4,634 shares Expires 2023-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:31 UTC |
ROMRELL LARRY EDirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 4,634 | Not disclosed Strike: $29.22 | Not disclosed |
DisclosureSEC source: 0001570585-20-000131 · wf-form4_158767745571321.xml · derivative · entry 1 ROMRELL LARRY E · CIK 0001120556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 4,634 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 17:28 UTC |
DICK JOHN WDirector
|
GrantShare Option C (right to buy) · Derivative | 4,614 | Not disclosed Strike: $28.82 | Not disclosed |
DisclosureSEC source: 0001570585-20-000125 · wf-form4_158767730915013.xml · derivative · entry 6 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,614 Underlying: Class C Ordinary Shares · 4,614 shares Expires 2023-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 17:28 UTC |
DICK JOHN WDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 4,614 | Not disclosed Strike: $28.82 | Not disclosed |
DisclosureSEC source: 0001570585-20-000125 · wf-form4_158767730915013.xml · derivative · entry 5 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 4,614 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 17:28 UTC |
DICK JOHN WDirector
|
GrantShare Option C (right to buy) · Derivative | 9,985 | Not disclosed Strike: $26.77 | Not disclosed |
DisclosureSEC source: 0001570585-20-000125 · wf-form4_158767730915013.xml · derivative · entry 4 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,985 Underlying: Class C Ordinary Shares · 9,985 shares Expires 2023-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 17:28 UTC |
DICK JOHN WDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 9,985 | Not disclosed Strike: $26.77 | Not disclosed |
DisclosureSEC source: 0001570585-20-000125 · wf-form4_158767730915013.xml · derivative · entry 3 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 9,985 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 17:28 UTC |
DICK JOHN WDirector
|
GrantShare Option A (right to buy) · Derivative | 4,634 | Not disclosed Strike: $29.22 | Not disclosed |
DisclosureSEC source: 0001570585-20-000125 · wf-form4_158767730915013.xml · derivative · entry 2 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,634 Underlying: Class A Ordinary Shares · 4,634 shares Expires 2023-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 17:28 UTC |
DICK JOHN WDirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 4,634 | Not disclosed Strike: $29.22 | Not disclosed |
DisclosureSEC source: 0001570585-20-000125 · wf-form4_158767730915013.xml · derivative · entry 1 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 4,634 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:28 UTC |
CURTIS MIRANDADirector
|
GrantShare Option C (right to buy) · Derivative | 4,614 | Not disclosed Strike: $28.82 | Not disclosed |
DisclosureSEC source: 0001570585-20-000124 · wf-form4_158767728408441.xml · derivative · entry 6 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,614 Underlying: Class C Ordinary Shares · 4,614 shares Expires 2023-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:28 UTC |
CURTIS MIRANDADirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 4,614 | Not disclosed Strike: $28.82 | Not disclosed |
DisclosureSEC source: 0001570585-20-000124 · wf-form4_158767728408441.xml · derivative · entry 5 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 4,614 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:28 UTC |
CURTIS MIRANDADirector
|
GrantShare Option C (right to buy) · Derivative | 9,985 | Not disclosed Strike: $26.77 | Not disclosed |
DisclosureSEC source: 0001570585-20-000124 · wf-form4_158767728408441.xml · derivative · entry 4 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,985 Underlying: Class C Ordinary Shares · 9,985 shares Expires 2023-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:28 UTC |
CURTIS MIRANDADirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 9,985 | Not disclosed Strike: $26.77 | Not disclosed |
DisclosureSEC source: 0001570585-20-000124 · wf-form4_158767728408441.xml · derivative · entry 3 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 9,985 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:28 UTC |
CURTIS MIRANDADirector
|
GrantShare Option A (right to buy) · Derivative | 4,634 | Not disclosed Strike: $29.22 | Not disclosed |
DisclosureSEC source: 0001570585-20-000124 · wf-form4_158767728408441.xml · derivative · entry 2 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,634 Underlying: Class A Ordinary Shares · 4,634 shares Expires 2023-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.